Subtype
Thyroid Gland Neoplasm
CI-CAN-00001600Explore in graph →
Non-malignant189 active trials10 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001600Explore in graph →
Clinical trials
891 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07704658 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 4 | 12 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07600580 | The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response | recruiting | Phase 4 | 48 | University Hospital DubravaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05830500 |
| Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma |
| recruiting |
| Phase 4 |
| 360 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY |
| 1 |
| Jul 25, 2023 |
| clinicaltrials |
Data updated 22 days agoSource updated Aug 10, 2026source: clinicaltrials